What's new for 'Trypanosomatids' in PubMed

This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.

Sender's message:

Sent on Thursday, 2011 Apr 14
Search kinetoplastids OR kinetoplastid OR Kinetoplastida OR "trypanosoma brucei" OR leishmania OR brucei OR leishmaniasis OR "African trypanosomiasis"
Click here to view complete results in PubMed. (Results may change over time.)
To unsubscribe from these e-mail updates click here.

PubMed Results

Items 1 - 4 of 4

1.	J Biomed Nanotechnol. 2011 Feb;7(1):213-5. Nanoparticles containing nitric oxide donor with antileishmanial agent for synergistic effect against visceral leishmaniasis. Pandya S, Verma RK, Misra A. National Institute of Pharmaceutical Education and Research, Raebareli 229010, India. Abstract Poly(lactide-co-glycolide) nanoparticles (NP) containing Doxorubicin (DOX) along with a nitric oxide (NO) donor Sodium Nitroprusside (SNP) were prepared by solvent displacement. NO is expected to synergise with antileishmanial activity of DOX. Preformulation studies showed no significant interaction between DOX and SNP. DOX and SNP loaded NP had an average size of 352 nm with 48% entrapment efficiency and a drug content of 10% w/w. Biphasic drug release was observed in vitro, with an initial burst of DOX and SNP (approximately 26% and 35% respectively) followed by sustained release for over 72 hrs.
	PMID: 21485876 [PubMed - in process]

2.	J Biomed Nanotechnol. 2011 Feb;7(1):135-6. Development and characterization of doxorubicin loaded microparticles against experimental visceral leishmaniasis. Sharma S, Kumar P, Jaiswal A, Dube A, Gupta S. Nanomedicine Research Centre, Department of Pharmaceutics, I.S.F College of Pharmacy, Moga 142001, India. Abstract Visceral leishmaniasis (VL) is the most severe of all the forms of leishmaniasis and usually lethal if untreated. The present work aimed to develop and characterize doxorubicin loaded mannan conjugated microparticles against experimental visceral leishmaniasis for selective and targeted delivery of doxorubicin to the macrophages of liver and spleen for the effective chemotherapy of VL. Macrophage targeting using doxorubicin loaded PLGA-microparticles would certainly improve the chemotherapy with reduced side effects against VL.
	PMID: 21485839 [PubMed - in process]

3.	J Biomed Nanotechnol. 2011 Feb;7(1):123-4. Development and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasis. Singodia D, Khare P, Dube A, Talegaonkar S, Khar RK, Mishra PR. Pharmaceutics Division, Central Drug Research Institute (CSIR), Lucknow 226001, India. Abstract The present study was aimed to assess the improvement of existing treatment regimens of Amphotericin B nanoconstrcuts which synergises with alginate for immunostimulation against visceral leishmaniasis. The particle size of Lip-nano (Plain AmB nanoconstructs) and Alg-Lip-nano (alginate capped Lip-nano) was 108.3 +/- 4.3 and 134.2 +/- 5.1 while zeta potential was (+) 28.4 +/- 3.3 and (-) 19.8 +/- 2.1 respectively. Percentage of parasite inhibition (intramacrophagic amastigotes) at 0.1 microg/ml conc. of AmB in case of Alg-Lip-nano (58%) was significantly higher (P = 0.05) compared to Lip-nano (48%). This supports that alginate coating over particles can activate macrophages to synergistically act with AmB in effective killing of parasite. This observation generates interest that immunotherapy with chemotherapeutic activity of AmB can effectively increase cure rate in visceral leishmaniasis.
	PMID: 21485834 [PubMed - in process]

4.	J Biomed Nanotechnol. 2011 Feb;7(1):118-20. Loading and release of amphotericin-B from biodegradable poly(lactic-co-glycolic acid) nanoparticles. Verma RK, Pandya S, Misra A. Pharmaceutics Division, Central Drug Research Institute (CSIR), M. G. Marg, Lucknow 226001, India. Abstract Amphotericin B (AmB)-loaded poly(lactic-co-glycolic acid, PLGA) nanoparticles (NP) were prepared by solvent displacement. NP of size 160.7 +/- 10.45 nm, with a polydispersity index of 0.093 +/- 0.012 and a zeta-potential of -15.5 +/- 7.2 mV had satisfactory drug entrapment efficiency (42.5 +/- 6.41%). Biphasic drug release characterized by an initial burst followed by subsequent sustained release was observed. Applicability against visceral leishmaniasis and cancer is under investigation.
	PMID: 21485832 [PubMed - in process]